Updates in Colorectal Cancer Screening Recommendations

This portion of our HCPLive peer-to-peer discussion on the importance of colorectal cancer (CRC) screening focuses on recent updates in screening recommendations to account for CRC’s growing impact on younger patient populations as well as the advent of new screening modalities.

In this video, our moderator Michael Sapienza is joined by Frank Colangelo, MD, Gursimran Kochhar, MD, and Thomas Imperiale, MD, as the experts engage in a discussion about the growing number of screening options available to patients, additionally highlighting the importance of recognizing the differences between and known limitations to these tests.

Sapienza introduces the topic and poses the question of how the conversation surrounding recommended CRC screening modalities has changed in recent years, additionally inquiring about differences between these choices and their impact on patient acceptance and accessibility. Colangelo provides his perspective on how this has positively impacted primary care doctors’ efforts to get their patients screened, a sentiment Kochhar also mentions in his response as he describes the benefit of having other screening options to offer patients who may not be able to get a colonoscopy.

Sapienza then asks Imperiale for his insight regarding the latest advancements in noninvasive CRC screening measures, to which Imperiale responds that although this “fast-moving area” has been mostly positive, it is also important to be aware of the limitations of these new screening modalities.

Check out the rest of our discussion:

Part 1: Updates in Colorectal Cancer Screening Recommendations

Part 2: Pressing Challenges in Colorectal Cancer Screening

Part 3: Reaching Patients in Need of Screening for Colorectal Cancer

Part 4: Navigating Patient Histories, Risk Factor Conversations in CRC Screening

Part 5: Appropriate Guidance for CRC Screening Age, Role of Advocacy Organizations

Our Experts:

Michael Sapienza, chief executive officer of the Colorectal Cancer Alliance, the largest colon cancer advocacy group in the country, and member of the American Cancer Society’s National Colorectal Cancer Roundtable steering committee.

Frank Colangelo, MD, an internist, vice president, and chief quality officer for Premier Medical Associates, a large multispecialty group within Allegheny Health Network as well as a member of the American Cancer Society’s National Colorectal Cancer Roundtable steering committee.

Gursimran Kochhar, MD, a gastroenterologist, associate division chief of the Department of Gastroenterology and Hepatology, and medical director of Endoscopic Innovations at Allegheny Health Network.

Thomas Imperiale, MD, principal investigator of the BLUE-C trial, research scientist at Regenstrief Institute, and Lawrence Lumeng Professor of Gastroenterology and Hepatology at Indiana University School of Medicine.

L to R: Michael Sapienza; Gursimran Kochhar, MD; Thomas Imperiale, MD; Frank Colangelo, MD

Imperiale has no relevant disclosures to report. Colangelo has no disclosures to report. Relevant disclosures for Kochhar include CorEvitas Research, Eli Lilly, Boston Scientific Endoscopy, Olympus Endoscopy, and Pentax Endoscopy. Sapienza has no relevant disclosures to report.